Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies Journal Article
| Authors: | Liu, C. Y.; Francis, J. H.; Brodie, S. E.; Marr, B.; Pulido, J. S.; Marmor, M. F.; Abramson, D. H. |
| Article Title: | Retinal toxicities of cancer therapy drugs: Biologics, small molecule inhibitors, and chemotherapies |
| Abstract: | PURPOSE: To review reported retinal side effects from current cancer therapy drugs. METHODS: Retinal toxicities from ophthalmologic or oncologic case reports, case series, and clinical trials were identified by a systematic literature search using Lexicomp and PubMed. RESULTS: Four biologics, 8 small molecule inhibitors, and 17 traditional chemotherapy agents had reported retinal side effects. For biologics, interferon alpha 2b was associated with retinopathy, denileukin diftitiox with pigmentary retinopathy, ipilimumab with a Vogt-Koyanagi-Harada-like syndrome, and trastuzumab with retinal ischemia. For small molecule inhibitors, v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors were associated with uveitis, mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitors with pigment epithelium detachments, and tyrosine kinase inhibitors with macular edema. Steroid antagonists were associated with crystalline retinopathy and macular edema. Nitrosoureas, platinum analogs, and cytosine arabinoside were associated with retinal vascular occlusions. Antimicrotubular agents were associated with cystoid macular edema but without fluorescein leakage. Retinoic acid derivatives were associated with impaired night vision, and mitotane was associated with a pigmentary retinopathy and papilledema. CONCLUSION: Certain agents used in the treatment of systemic cancer are associated with ocular complications. Awareness of these complications will allow early detections and maybe reversal of some of the ocular problems. Copyright © by Ophthamic Communications Society, Inc. |
| Keywords: | cancer chemotherapy; unclassified drug; fludarabine; review; cisplatin; interferon; side effect; chemotherapy; cytarabine; methotrexate; antineoplastic agent; imatinib; alpha2b interferon; carboplatin; ipilimumab; unindexed drug; mitogen activated protein kinase inhibitor; cancer therapy; carmustine; procarbazine; tyrosine kinase inhibitors; monoclonal antibody; papilledema; medline; retina detachment; retinopathy; retina; nitrosourea; platinum derivative; drug toxicity; trastuzumab; oxaliplatin; eye toxicity; mitotane; n (2,3 dihydroxypropoxy) 3,4 difluoro 2 (2 fluoro 4 iodoanilino)benzamide; uveitis; virus oncogene; denileukin diftitox; retina macula cystoid edema; side effects; crizotinib; vemurafenib; retina ischemia; dabrafenib; trametinib; retinoic acid derivative; cancer; human; retinal toxicities; biologic agent; chemotherapy agent; msc 1936369; small molecule inhibitor; dark adaptation; retina blood vessel occlusion; retina macula edema; vogt koyanagi syndrome |
| Journal Title: | Retina |
| Volume: | 34 |
| Issue: | 7 |
| ISSN: | 0275-004X |
| Publisher: | Wolters Kluwer |
| Date Published: | 2014-07-01 |
| Start Page: | 1261 |
| End Page: | 1280 |
| Language: | English |
| DOI: | 10.1097/iae.0000000000000242 |
| PROVIDER: | scopus |
| PUBMED: | 24949716 |
| DOI/URL: | |
| Notes: | Export Date: 1 August 2014 -- CODEN: RETID -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work